abstract: OBJECTIVES: To examine the association between atypical antipsychotic medications and incident treatment for @entity6 or @entity407 in elderly adults without diagnoses of @entity161 or @entity162 . DESIGN: Two case-control studies using medical and pharmacy claims data. SETTING: United States managed care population from multiple insurance plans. @entity1 : Individuals aged 65 and older enrolled in a Medicare Advantage or commercial (health maintenance organization) managed care health plan in the western United States with no claims indicating diagnosis of @entity161 or @entity162 in the 1 year pre-index period. Cases were defined as @entity1 newly initiated on an antidiabetic (n = 13,075) or antihyperlipidemic (n = 63,829) medication on the index date. For the new @entity6 analysis, 65,375 controls were matched to cases based on age, sex, health-plan type, and index date year. In the new @entity407 analysis, 63,829 controls were matched to cases based on the same variables. MEASUREMENTS: Conditional logistic regressions were performed to determine the odds of initiated antidiabetic or antihyperlipidemic medication for @entity1 exposed to atypical antipsychotics compared with those with no exposure. The models included comorbidities possibly associated with the outcome. RESULTS: Exposure to atypical antipsychotics was associated with significantly greater adjusted odds of starting an antidiabetic medication (1.32, 95% confidence interval (CI) = 1.10-1.59) but significantly lower odds of starting an antihyperlipidemic medication (0.76, 95% CI = 0.67-0.87). CONCLUSION: Use of atypical antipsychotics in older adults for conditions other than @entity161 and @entity162 was associated with incident treatment of @entity6 but not of @entity407 , suggesting that older adults may be susceptible to the adverse metabolic consequences of these agents.

title: New-onset treatment-dependent @entity6 and @entity407 associated with atypical antipsychotic use in older adults without @entity161 or XXXX .

entities_list: @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia']

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'PARTICIPANTS', 'persons']

entities_list: @entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar disorder']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

answer: @entity162 :: (MESH:D001714,Disease) :: ['bipolar disorder']


abstract: OBJECTIVES: To measure eye blink frequency as a measure of trigeminal stimulation of the eye. @entity1 subjects were exposed to oxidation mixtures representative of reactive indoor pollutants and clean air, from which relative changes in blink frequencies were measured. METHOD: Male subjects ( n=8) were exposed for 20 min to @entity4108 oxidation products (LOPs), @entity21045 oxidation products (IOPs), @entity1507 radicals ( @entity8326 ), their residual reactants, and clean air at 20% relative humidity. A baseline blink frequency was measured prior to and following each exposure (2 x 8 min). The subjects were exposed locally in the @entity735 . Blinking was video-recorded and evaluated for full sessions of 36 min while the subjects viewed an educational film. The initial @entity9534 concentrations were one to two orders of magnitude higher than mean indoor concentrations. RESULTS: The mean blink frequency increased significantly during subjects' exposure to gas-phase oxidation products at lower part-per-billion (ppb) levels of LOPs, 42% ( P<0.0001) and @entity8326 , 21% ( P<0.022), compared with that at baseline. Neither the residual reactants nor clean air changed the blink frequency significantly. The findings coincided with qualitative reporting of weak eye @entity146 symptoms. CONCLUSIONS: Changes in blink frequency appear to be a promising measure of trigeminal stimulation from exposure to eye irritants in ppb levels. Gaseous products of @entity4108 and @entity1787 , and reactive radicals may cause eye @entity146 indoors.

title: @entity735 as a measure of trigeminal stimulation by exposure to @entity4108 oxidation products, @entity21045 oxidation products and XXXX radicals.

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['irritation']

entities_list: @entity4108 :: ('MESH:C008281', 'Chemical') :: ['limonene']

entities_list: @entity1507 :: ('CHEBI:48107', 'Chemical') :: ['nitrate']

entities_list: @entity9534 :: ('CHEBI:35186', 'Chemical') :: ['terpene']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['non-dominant eye and single blind in random order']

answer: @entity1507 :: (CHEBI:48107,Chemical) :: ['nitrate']


abstract: PURPOSE: The primary aims of this study were to delineate trends in medical comorbidity and surgical approach in @entity1 with renal @entity731 and @entity2629 . METHODS: We reviewed 1643 @entity1 undergoing renovascular surgery between 1970 and 1993. We focused on those with the most advanced @entity8 (serum @entity1011 > 2 mg/dl) (n = 402). Attention was focused specifically on trends in sex, age, medical risk factors, surgical technique (bypass vs endarterectomy), and outcome including eventual need for long-term dialysis. RESULTS: From 1970 to 1980, 652 @entity1 underwent renovascular surgery, with 98 (15%) having a serum @entity1011 > 2 mg/dl. From 1980 to 1993, the percentage of @entity1 with @entity177 increased to 31% (304 of 991) (p < 0.001). Gender distribution did not change, but median age rose from 63.5 years in the first decade to 68.0 in the past 13 years. A remarkable increase in all serious medical risk factors also occurred (first vs second decade). Another significant trend was a shift toward bilateral simultaneous transaortic endarterectomy (18% from 1980 to 1985 vs 53% from 1986 to 1993; p < 0.01), which simplified and achieved complete renal revascularization, especially in @entity1 having @entity2791 and those needing aortic grafting for occlusive or @entity439 (56% from 1970 to 1980 vs 75% from 1980 to 1993). @entity1 at low risk (0 to 1 comorbid medical conditions) had a 30-day mortality rate of 5.6% compared with @entity1 at high risk (2 to 3 comorbid conditions) (15.5%) (p = 0.016). The eventual need for long-term dialysis remained low (9%) for @entity1 with a preoperative serum @entity1011 of 2 to 2.9 mg/dl compared with those with a serum @entity1011 greater than 3 mg/dl (35%, p < 0.01). CONCLUSIONS: In the past 20 years, there has been a remarkable increase in the medical comorbidity and extent of @entity2333 in @entity1 undergoing surgical revascularization for advanced @entity2792 and @entity177 . However, the surgical approach can be simplified and expedited by bilateral transaortic endarterectomy, and the risk of late dialysis can be reduced significantly by operating before the serum @entity1011 exceeds 3 mg/dl.

title: @entity2792 and XXXX : trends in medical comorbidity and surgical approach from 1970 to 1993.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['kidney disease']

entities_list: @entity2792 :: ('MESH:D006978', 'Disease') :: ['renovascular hypertension']

entities_list: @entity2791 :: ('MESH:D012078', 'Disease') :: ['multiple renal artery stenoses']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysmal disease']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity2333 :: ('MESH:D001018', 'Disease') :: ['aortic disease']

answer: @entity177 :: (MESH:D051437,Disease) :: ['renal insufficiency']


abstract: OBJECTIVE: Right @entity123 and subsequent dysfunction is common in @entity1 with @entity4297 , but the molecular mechanisms underlying change from adaptive @entity1184 to dysfunction remain elusive. We used the novel technique of proteomics to characterize protein changes in right ventricular myocardium in a neonatal model of @entity8158 and @entity409 . METHODS: Twelve neonatal piglets were equally randomized to pulmonary artery banding (PAB group), or sham operation (thoracotomy without banding). After 4 weeks, right ventricular morphology and function were assessed in vivo using magnetic resonance imaging. Animals were humanely killed. Proteomics of right ventricular myocardium was performed. Purified right ventricular proteins were separated by 2-dimensional difference gel electrophoresis using fluorescent @entity10502 dyes. After gel imaging, software analysis revealed protein spots differentially expressed between the 2 groups; these spots were excised and identified by mass spectrometry. RESULTS: On magnetic resonance imaging, animals with pulmonary artery banding demonstrated significant @entity8158 , @entity384 , and mild @entity73 (right ventricular ejection fraction 39.8% +/- 15% vs 56.7% +/- 10% controls; P < .05). Right ventricular free wall mass on harvest confirmed @entity8158 . Proteomic analysis revealed 18 proteins that were significantly differentially expressed: 5 structural proteins, 6 metabolic enzymes, 2 stress proteins, and 5 miscellaneous proteins. Expression of calsarcin-1 and @entity10274 was increased, as were certain metabolic enzymes, although F(1)-ATPase beta-chain and @entity1457 protein 70 decreased. CONCLUSIONS: This is the first study characterizing right ventricular protein changes in a large animal model specifically capturing the change from compensated to maladaptive @entity1184 . These findings can guide future work at elucidating the mechanisms in the pathophysiology of neonatal @entity67 .

title: Right @entity123 with XXXX : A proteomics study in a neonatal model.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophy']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['cavity dilatation']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['systolic impairment']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['early dysfunction']

entities_list: @entity1457 :: ('MESH:D012769', 'Disease') :: ['heat shock']

entities_list: @entity8158 :: ('MESH:D017380', 'Disease') :: ['right ventricular hypertrophy']

entities_list: @entity123 :: ('MESH:D024741', 'Disease') :: ['ventricular hypertrophy']

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['right ventricular hypertrophy and dysfunction']

entities_list: @entity4297 :: ('MESH:D006330', 'Disease') :: ['congenital heart defects']

answer: @entity409 :: (MESH:D008107,Disease) :: ['early dysfunction']


abstract: Twenty four @entity1 with @entity1072 ( @entity1072 ) and advanced @entity1893 ( @entity1893 ) were treated with @entity3118 given at a dose of 25 mg/m2, intravenously daily for 5 days, every 28 days. Ten of the @entity1 with @entity1893 were in terminal leukemic phase. All @entity1 had received previous chemotherapy, most with multiple regimens. @entity1 received a mean of 5.1 cycles (range 1-9). 4 @entity1 --one with @entity1072 and 3 with @entity1893 --achieved a complete remission, while 7 @entity1893 and 3 @entity1072 @entity1 had a partial response. Two @entity1 remain in complete remission 23 and 25 months after completion of therapy. One @entity1 underwent successful autologous bone marrow transplantation after achieving a complete remission, while two others had marrow cryopreserved during complete remission. The drug was well tolerated and @entity137 was mild. In 9 of the 122 given cycles @entity1 required hospitalization. In conclusion, @entity3118 is active in refractory @entity1 with @entity1072 and @entity1893 and induces complete and partial remissions in some. It seems that @entity3118 could be used as primary therapy in these disorders in the future.

title: Activity of @entity3118 in XXXX and low grade @entity1893 --the Jerusalem experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity1072 :: ('MESH:D015451', 'Disease') :: ['CLL', 'refractory chronic lymphocytic leukemia']

entities_list: @entity3118 :: ('MESH:C024352', 'Chemical') :: ['Fludarabine']

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ['low grade lymphoma', 'LGL']

answer: @entity1072 :: (MESH:D015451,Disease) :: ['refractory chronic lymphocytic leukemia']


abstract: This study examined the effect of various levels of @entity8 on the probability of achieving free drug concentrations that exceed the MIC for 50% of the dosing interval (50% fT > MIC) for traditional and extended-infusion @entity3400 - @entity7120 (TZP) dosing strategies. It also identified optimal renal dosage adjustments for traditional and extended-infusion dosing schemes that yielded probability of target attainment (PTA) and exposure profiles that were isometric to those of the parent regimens. Data from 105 @entity1 were analyzed using the population pharmacokinetic modeling program BigNPAG. To assess the effect of @entity1011 clearance ( @entity14488 ) on overall clearance, TZP clearance was made proportional to the estimated @entity14488 . A Monte Carlo simulation (9,999 subjects) was performed for the traditional dosing scheme (4.5 g infused during 30 min every 6 h) and the extended-infusion TZP dosing scheme (3.375 g infused during 4 h every 8 h). The fraction of simulated subjects who achieved 50% fT > MIC was calculated for the range of @entity3400 MICs from 0.25 to 32 mg/liter and stratified by @entity14488 . The traditional TZP regimen displayed the greatest variability in PTA across MIC values, especially for MIC values exceeding 4 mg/liter, when stratified by @entity14488 . In contrast, the PTA for the extended-infusion TZP regimen exceeded >or=80% for MIC values of <or=8 mg/liter across all @entity14488 strata. All regimens were associated with suboptimal PTA for MIC values of >or=32 mg/liter irrespective of the @entity14488 . The @entity14488 adjustments for traditional and extended-infusion TZP dosing regimens should be considered at a @entity14488 of <or=20 ml/min.

title: Identification of optimal renal dosage adjustments for traditional and extended-infusion XXXX - @entity7120 dosing regimens in hospitalized @entity1 .

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment']

entities_list: @entity7120 :: ('MESH:C043265', 'Chemical') :: ['tazobactam']

entities_list: @entity3400 :: ('MESH:D010878', 'Chemical') :: ['piperacillin']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

answer: @entity3400 :: (MESH:D010878,Chemical) :: ['piperacillin']


abstract: To study the role of cell-mediated immunity in chronic @entity1956 (cHB) we have cloned T cells from liver biopsies of 14 @entity1 with cHB. As a first step, T cell lines were established from lymphocytes infiltrating the liver by culturing the biopsied specimens with autologous feeder cells and @entity1199 ( @entity1199 ). Fifty-eight clones obtained by limiting dilution showed phenotypic stability over periods of 2-26 weeks. Of the 58 clones 50 were of the "cytotoxic/suppressor" T cell subset ( @entity405 ) as defined by the monoclonal antibody T811. Only 8 of 58 clones were of the "helper/inducer" phenotype ( @entity404 ) as defined by the monoclonal antibody T151. Functional studies on 9 clones (7 of @entity405 + phenotype, 2 of @entity404 + phenotype) revealed high cytotoxic activity of all of these clones in a lectin-dependent cell-mediated cytotoxicity assay reflecting the killing capacity of cytotoxic T lymphocytes. All 9 clones lacked significant natural killer activity, while two additional @entity405 + clones that also expressed the VEP13 antigen showed significant natural killer activity. For none of the clones tested could killer cell activity (ADCC) be demonstrated. The studies demonstrate that the clonal expansion of T lymphocytes from liver biopsies of @entity1 with cHB in the absence of detectable antigen is possible. The propagation of in vivo activated cytolytic T lymphocytes points to an active role of these cells in the pathogenesis of this disease.

title: Cytolytic T cell clones derived from liver tissue of @entity1 with chronic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1956 :: ('MESH:D006509', 'Disease') :: ['hepatitis B']

answer: @entity1956 :: (MESH:D006509,Disease) :: ['hepatitis B']


abstract: Using continuous @entity1 @entity43 cell lines, i.p. xenografts were successfully established in @entity19 from four of four attempts. When @entity5 material was used, xenografts grew in 8 of 10 attempts. From these eight, three passageable xenograft cell lines have been established. To our knowledge, this is the first report published of such xenografts. I.p. xenografts closely mimic the clinical behavior of @entity1 @entity43 , and those developed from @entity5 material maintain close morphological similarity to the parent @entity5 . When expression of placental alkaline phosphatase and the @entity5 associated antigens defined by the monoclonal antibodies HMFG1, HMFG2, AUA1, and F36/22 by these models was determined, those i.p. xenografts derived from @entity5 material exactly matched the original @entity5 , while none of the xenografts derived from the cell lines expressed these antigens. These models will be useful for investigating the biology and treatment of @entity43 .

title: Intraperitoneal xenografts of @entity1 XXXX in @entity19 .

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumor']

answer: @entity43 :: (MESH:D010051,Disease) :: ['epithelial ovarian cancer']


abstract: BACKGROUND: We analyzed perioperative platelet counts as a potential clinical marker for survival after transthoracic en bloc resection for @entity418 . Recent data described preoperative @entity1148 in @entity5 to be associated with poor prognosis. METHODS: A retrospective analysis from a prospective database (1997-2006) was performed for 291 consecutive @entity1 with @entity418 who underwent transthoracic en bloc esophagectomy and extended lymphadenectomy. @entity1544 was found in 47.0% and @entity420 in 50.9% (2.1% had rare histologies). Neoadjuvant chemoradiation was performed in 152 (52%) @entity1 . Platelet counts before surgery and on postoperative days (PODs) 1, 10, and 30 were evaluated. We used the published cutoff value of 293     10(9)/l (mean of 80 healthy controls      standard deviation) for platelet counts. RESULTS: High platelet counts before surgery missed significance for poorer survival (p  =  0.054). Following a perioperative fall in thrombocytes, a significant rise at POD 10 after surgery was evident. Platelet counts of more than 293     10(9)/l at this time correlated with a significantly improved survival rate (p  =  0.027). @entity1 with no increase in thrombocytes until POD 10 had significantly poorer survival (p  =  0.012). Multivariate analysis confirmed that a thrombocyte increase between the preoperative count and that on POD 10 is an independent prognostic indicator (p  =  0.035) for @entity1 with completely (R0) resected @entity5 . CONCLUSIONS: An increase in platelet counts measured on POD 10 following transthoracic en bloc esophagectomy and extended lymphadenectomy is an independent prognostic indicator for improved survival in @entity1 with @entity418 .

title: Increased platelet counts after transthoracic en bloc resection for XXXX is associated with significantly improved survival.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1148 :: ('MESH:D013922', 'Disease') :: ['thrombocytosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors', 'malignancies']

entities_list: @entity1544 :: ('MESH:D018307', 'Disease') :: ['Squamous cell cancer']

entities_list: @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

answer: @entity418 :: (MESH:D004938,Disease) :: ['esophageal cancer']


abstract: The long-term clinical results of surgical treatment for @entity1318 were reviewed in 35 @entity1 having a minimum follow-up of 10 years. Group A (n = 22) are those @entity1 whose first procedure (myotomy and Belsey partial fundoplication) was done at our hospital. Group B (n = 13) are those who had undergone one or more previous operations elsewhere. In group A good to excellent results occurred in 21/22 @entity1 (95%) at 1 year, 17/22 (77%) at 5 years, 15/22 (68%) at 10 years, 11/16 (69%) at 15 years, and 6/9 (67%) at 20 or more years. Two @entity1 underwent early reoperation (2 and 5 years) for @entity1282 due to @entity445 . Three @entity1 underwent esophagectomy (7, 19, and 23 years) and one @entity1 underwent an antrectomy and Roux-en-Y diversion (23 years) for late-onset complications of reflux. Three of 13 group B @entity1 had had multiple prior operations and had severe @entity16 at presentation and underwent immediate esophagectomy. Ten @entity1 had one or more conservative operations in our hospital, and 4 of these eventually required esophagectomy for disabling reflux. Therefore, there were 10 @entity1 (groups A+B) who underwent esophageal resection, all but 1 of whom had endoscopically documented reflux and 5 of whom had peptic strictures. Six of the 10 esophagectomies were performed more than 10 years (13 to 23 years) after the first operation.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Long-term results in surgically managed XXXX .

entities_list: @entity1318 :: ('MESH:D004931', 'Disease') :: ['esophageal achalasia']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['reflux damage']

entities_list: @entity445 :: ('MESH:C536298', 'Disease') :: ['incomplete myotomy']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']

answer: @entity1318 :: (MESH:D004931,Disease) :: ['esophageal achalasia']


abstract: Pulsed-Doppler derived @entity450 ( @entity450 ) has been widely used for evaluating left ventricular (LV) diastolic function. The grading of LV @entity67 is feasible by the ratio of early to late diastolic inflow velocities (E/A): normal: E/A > 1, grade I: E/A < 1 (abnormal relaxation pattern), grade II: E/A > 1 (pseudonormal pattern), grade III: E/A > > 1 (restrictive pattern), and grade IV: E/A > > 1 (irreversible restrictive pattern). Pulmonary venous flow pattern is also used for evaluation of LV @entity67 , especially to differentiate a normal from pseudonormal @entity450 pattern. The ratio of systolic to diastolic pulmonary venous flow (S/D) >1 is normal and S/D < 1 is regarded as pseudonormal. Recently, tissue Doppler imaging (TDI) has been introduced as a new diagnostic tool for LV @entity67 . The mitral annular velocity obtained by TDI is used for a preload-independent index of LV diastolic function. The ratio of early transmitral inflow to mitral annular velocity (E/Ea) related well to pulmonary capillary wedge pressure. In particular, E/Ea > 15 strongly suggested elevated PCWP and LV filling pressure. Therefore, analysis of @entity450 and PVF patterns by pulsed Doppler and Ea by TDI is useful for diagnosing the uncompensated state of @entity712 . Furthermore, the @entity450 pattern is utilized to predict the prognosis of @entity1 with @entity712 . @entity1 with an irreversible restrictive filling pattern have high mortality, whereas those with, reversible restrictive filling have a high probability of improvement of @entity712 .

title: [Predictive significance of evaluation of left ventricular diastolic function in @entity1 with XXXX ].

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['diastolic dysfunction']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity450 :: ('MESH:D006940', 'Disease') :: ['transmitral flow', 'TMF']

answer: @entity712 :: (MESH:D006333,Disease) :: ['heart failure']


abstract: Objective. To describe a profoundly immunocompromised ( @entity8544 ) @entity1 with @entity326 who developed @entity8479 ( @entity8479 ) and was successfully treated with surgical decompression. Design. Individual case report. Setting. Pediatric intensive care unit of a tertiary @entity1 's hospital. @entity1 . A 32-month-old male with @entity11807 who underwent bone marrow transplantation (BMT) 5 days prior to developing @entity326 secondary to Streptococcus viridans and @entity526 @entity8479 developed after massive fluid resuscitation, leading to cardiopulmonary instability. Interventions. Emergent surgical bedside laparotomy and silo placement. Measurements and Main Results. The @entity1 's cardiopulmonary status stabilized after decompressive laparotomy. The abdomen was closed and the @entity1 survived to hospital discharge without @entity299 . Conclusions. The use of laparotomy and silo placement in an unengrafted BMT @entity1 with @entity8479 and @entity326 did not result in additional complications. Surgical intervention for @entity8479 is a reasonable option for high risk, profoundly immunocompromised @entity1 .

title: Decompressive abdominal laparotomy for XXXX in an unengrafted bone marrow recipient with @entity326 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient', 'Patient', 'child']

entities_list: @entity326 :: ('MESH:D012772', 'Disease') :: ['septic shock']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli']

entities_list: @entity8479 :: ('MESH:D059325', 'Disease') :: ['abdominal compartment syndrome', 'ACS']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac, respiratory, or renal dysfunction']

entities_list: @entity8544 :: ('MESH:D005254', 'Disease') :: ['panleukopenia']

entities_list: @entity11807 :: ('MESH:D005199', 'Disease') :: ['Fanconi anemia']

answer: @entity8479 :: (MESH:D059325,Disease) :: ['abdominal compartment syndrome']


abstract: BACKGROUND: Elevation in total and low-density lipoprotein @entity165 levels and a decrease in high-density lipoprotein @entity165 plasma concentrations are common in heart transplant recipients. The pathogenesis of this @entity407 after heart transplantation is complex. Currently available antilipemic agents are difficult to use because their adverse effects are potentiated by immunosuppressor treatment. The present investigation was carried out to test the safety and efficacy of @entity5753 and @entity10569 in 18 @entity1 with @entity407 after heart transplantation. METHODS: In this crossover study, after 3 months of dietary recommendations, the subjects were randomly assigned to an 8-week period of @entity5753 treatment (10 mg/day) followed by an additional 8-week period of treatment with @entity10569 (400 mg/day) or vice versa. The two treatments were separated by an 8-week washout period. RESULTS: Both drugs reduced total and low-density lipoprotein @entity165 and apoprotein B concentrations. High-density lipoprotein @entity165 was only increased with @entity10569 . The total @entity165 /high-density lipoprotein @entity165 and low-density lipoprotein @entity165 /high-density lipoprotein @entity165 ratios were decreased under both treatments, but these changes were greater with @entity10569 . @entity1675 levels increased with @entity5753 . @entity10569 produced a rise in high-density lipoprotein @entity165 and reduced total and very low-density lipoprotein @entity1674 and very low-density lipoprotein @entity165 . Both drugs decreased intermediate density lipoprotein @entity165 and @entity412 levels, but the effect of @entity10569 on intermediate-density lipoprotein @entity1674 was significantly greater. The two drugs were well tolerated and liver enzymes, @entity908 kinase, and renal function remained stable.

title: @entity5753 versus @entity10569 for XXXX treatment after heart transplantation.

entities_list: @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipemia']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity5753 :: ('MESH:D008148', 'Chemical') :: ['lovastatin']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity10569 :: ('MESH:D001629', 'Chemical') :: ['bezafibrate', 'Bezafibrate']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity407 :: (MESH:D006949,Disease) :: ['hyperlipemia']


abstract: CONTEXT: @entity308 consistently predicts recurrent events and mortality in @entity1 with @entity1187 ( @entity1187 ), but it @entity4660 core diagnostic criteria with distinct biological correlates- @entity308 mood and @entity4270 ( @entity393 or interest). OBJECTIVE: To determine if @entity308 mood and/or @entity4270 predict 1-year medical outcomes for @entity1 with @entity1187 . DESIGN: Observational cohort study of post- @entity1187 @entity1 hospitalized between May 2003 and June 2005. Within 1 week of admission, @entity1 underwent a structured @entity146 interview assessing clinically impairing @entity308 mood, @entity4270 , and @entity308 ( @entity308 ). Also assessed were the Global Registry of Acute Coronary Events risk score, Charlson comorbidity index, left ventricular ejection fraction, antidepressant use, and @entity308 symptom severity using the Beck @entity308 Inventory. SETTING: Cardiac units of 3 university hospitals in New York and Connecticut. @entity1 : Consecutive sample of 453 @entity1 with @entity1187 (age, 25-93 years; 42% @entity1 ). MAIN OUTCOMES MEASURES: All-cause mortality (ACM) and documented major adverse @entity299 (MACEs)- @entity583 , hospitalization for unstable @entity951 , or urgent/emergency coronary revascularization)-actively surveyed for 1 year after admission. RESULTS: There were 67 events (16 deaths and 51 MACEs; 14.8%): 108 (24%) and 77 (17%) @entity1 had @entity4270 and @entity308 mood, respectively. Controlling for sex, age, and medical covariates, @entity4270 (adjusted hazard ratio, 1.58; 95% confidence interval, 1.16-2.14; P < .01) was a significant predictor of combined MACE and ACM, but @entity308 mood was not. @entity4270 continued to significantly predict outcomes (P < .05) when additionally controlling for @entity308 diagnosis or @entity308 symptom severity. Findings were confirmed using @entity308 mood and @entity4270 subscores from the Beck @entity308 Inventory in place of clinician interview ratings. CONCLUSIONS: @entity4270 identifies risk of MACE and ACM beyond that of established medical prognostic indicators, including @entity308 and @entity308 symptom severity. Correlates of @entity4270 may add to the understanding of the link between @entity308 and @entity299 .

title: Association of XXXX with recurrent major adverse @entity299 and mortality 1 year after @entity1187 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PARTICIPANTS']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['major depressive episode', 'MDE', 'Depression', 'depressed', 'depression', 'depressive']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

entities_list: @entity4270 :: ('MESH:D059445', 'Disease') :: ['Anhedonia', 'anhedonia']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events', 'heart disease']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['loss of pleasure']

answer: @entity4270 :: (MESH:D059445,Disease) :: ['anhedonia']


abstract: OBJECTIVES: This study sought to discover the incidence of permanent pacemaker (PPM) placement for @entity713 ( @entity713 ) after operative repair of perimembranous @entity1757 (PMVSD) in a large multi-institutional database and in the subgroup of @entity1 comparable to those considered for transcatheter device closure of PMVSD. BACKGROUND: @entity713 is a complication of operative repair of PMVSD and of device closure of this defect. Earlier reports do not report the incidence of @entity713 by VSD type. METHODS: The Pediatric Cardiac Care Consortium database was searched for all @entity1 who had operative PMVSD repair except those with abnormalities that increase risk of @entity713 . The @entity1 group was searched for those with subsequent PPM placement for @entity713 . Demographic data and time to PPM placement were available for all @entity1 . RESULTS: Of 4,432 @entity1 with PMVSD repair, 48 (1.1%) underwent PPM placement for @entity713 . The PPM group was more likely to have Down syndrome (41% vs. 18%; p < 0.001), was younger (mean age 14 vs. 26 months; p < 0.001), and had longer mean length of postoperative hospital stays (20 vs. 8 days; p < 0.001). The most significant risk factor for @entity713 was Down syndrome (odds ratio 3.62, 95% confidence interval 2.02 to 6.39; p < 0.005). Modal time to PPM placement was 7 days (range 0 to 4,078 days). Out of 1,877 @entity1 comparable to those currently considered for device closure, 13 (0.8%) underwent PPM placement after PMVSD repair. CONCLUSIONS: Operative @entity713 and PPM placement occurred in 1.1% of @entity1 in the total group and in 0.8% of @entity1 comparable to those considered for device closure of PMVSD. A PPM placement is more likely in @entity1 with Down syndrome. These data should be considered as devices are developed and in the future when counseling families about options for PMVSD closure.

title: Permanent pacemaker for @entity713 after operative repair of perimembranous XXXX .

entities_list: @entity713 :: ('MESH:D054537', 'Disease') :: ['AV block', 'Atrioventricular conduction block', 'atrioventricular conduction block']

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity1757 :: ('MESH:D006345', 'Disease') :: ['ventricular septal defect']

answer: @entity1757 :: (MESH:D006345,Disease) :: ['ventricular septal defect']


abstract: PURPOSE: To evaluate the role of allogeneic bone marrow transplantation (BMT) in recurrent @entity1893 . @entity1 AND METHODS: Between 1989 and 1994, 10 @entity1 with chemotherapy-refractory and recurrent @entity1893 were treated with myeloablative therapy and allogeneic BMT. All @entity1 had poor prognostic features and had been extensively pretreated. RESULTS: Eight @entity1 achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two @entity1 died of early complications. The actuarial survival and failure-free survival rates are both 80% +/- 12.6%. For surviving @entity1 , the duration of the current remission exceeds that of any previous remission achieved. CONCLUSION: These results compare favorably with those for autologous BMT. Allogeneic BMT offers considerable promise for the treatment of @entity1 with poor-prognosis @entity1893 . Its role should be further defined in prospective studies.

title: Allogeneic bone marrow transplantation for refractory and recurrent XXXX : the case for aggressive management.

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ['low-grade lymphoma']

entities_list: @entity1 :: ('9606', 'Species') :: ['PATIENTS', 'patients']

answer: @entity1893 :: (MESH:D008228,Disease) :: ['low-grade lymphoma']


abstract: Because of its potent ability to induce apoptosis, @entity8310 virus (VSV) is an attractive candidate as an oncolytic virus for @entity5 therapy. Previous studies have suggested that VSV selectively infects @entity5 cells due to defects in their antiviral responses making them more susceptible to VSV infection than normal cells. We tested this hypothesis in the @entity263 system by comparing LNCaP and @entity263 cells to benign @entity1 prostatic epithelial cells from @entity1 prostatectomy specimens. We compared the cell killing ability of a recombinant virus containing a wild-type (wt) M protein (rwt) and an isogenic M protein mutant virus (r @entity23337 ) that induces interferon (IFN) in infected cells and should display a greater selectivity for @entity5 cells. Our results showed that in single-cycle infection experiments, LNCaP cells were sensitive to killing by both wt and mutant viruses, while PC-3 cells were highly resistant to VSV-induced cell killing. LNCaP and benign prostate cells were similarly susceptible to both viruses, indicating that normal prostate cells are not inherently resistant to killing by VSV. In each of the cell lines, the rM51R- @entity23338 induced similar levels of apoptosis to rwt virus, showing that the M protein does not play a significant role in apoptosis induction by VSV in these cells. In multiple-cycle infection experiments, LNCaP cells were more sensitive than benign prostatic epithelial cells to virus-induced cell killing by rM51R- @entity23338 , but not rwt virus. Both viruses were equally effective at reducing LNCaP @entity5 volume in vivo following intratumoral and intravenous inoculation in @entity19 , while PC-3 @entity5 were resistant to VSV treatment. None of the @entity19 treated with rM51R- @entity23338 died as a result of @entity778 , while 50-71% of @entity19 treated with rwt virus succumbed to @entity778 . Similarly, when inoculated by the more sensitive intranasal route, the rM51R- @entity23338 was less pathogenic than the rwt virus from which it was derived. These results indicate that M protein mutant viruses are superior candidates as oncolytic viruses for therapies of @entity263 , but future strategies for use of VSV will require testing individual @entity5 for their susceptibility to @entity778 .

title: XXXX to wild type and M protein mutant @entity8310 viruses.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patient']

entities_list: @entity778 :: ('MESH:D015658', 'Disease') :: ['virus infection']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['PC-3 prostate tumor', 'prostate tumor', 'prostate tumors']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity8310 :: ('MESH:D054243', 'Disease') :: ['vesicular stomatitis']

entities_list: @entity23337 :: ('p|SUB|M|51|R,M', 'ProteinMutation') :: ['M51R-M']

answer: @entity263 :: (MESH:D011471,Disease) :: ['Sensitivity of prostate tumors']


abstract: In a previous report, we have shown that intracerebroventricular (icv) administration of the cytokine @entity10884 ( @entity10884 ) in the ovariectomized (OVX) @entity2608 results in the acute activation of the @entity774 and the inhibition of LH and FSH secretion. Here, we compare the @entity701 response to @entity10884 administration in OVX monkeys and in OVX animals replaced with @entity53 (E) to reproduce E concentrations typical of the early-mid follicular phase. @entity701 , LH and FSH were measured after an icv infusion of physiological saline or @entity10884 (2.1 or 4.2 micrograms/30 min) in both groups. E-containing capsules were implanted sc 5 days prior to the experiment. In OVX, E concentrations were < 5 pg/ml. @entity701 concentrations decreased throughout the afternoon after saline infusion (to 49.7 +/- 5.1% of baseline at 5 h; n = 7), but increased significantly after @entity10884 to 158.3 +/- 13.8% (n = 7). In OVXE, @entity701 also declined after saline (to 76.4 +/- 16.2%; n = 5). There were 2 types of response to @entity10884 : in grp 1 (mean E: 18.0 +/- 0.7 pg/ml), the @entity701 response was similar to that in OVX (160.8 +/- 17.0%; n = 5), while in grp 2 (E: 30.7 +/- 3.1 pg/ml), the @entity701 response was absent (66.6 +/- 7.2% of baseline at 5 h; NS vs saline in OVXE; n = 7). The @entity701 response to @entity10884 was restored in 2 monkeys when E was increased to > 100 pg/ml, confirming our previous observations.(ABSTRACT TRUNCATED AT 250 WORDS)

title: A 5-day XXXX therapy, in amounts reproducing concentrations of the early-mid follicular phase, prevents the activation of the hypothalamo-pituitary-adrenal axis by @entity10884 in the ovariectomized @entity2608 .

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol']

entities_list: @entity701 :: ('MESH:D006854', 'Chemical') :: ['Cortisol', 'cortisol']

entities_list: @entity2608 :: ('9544', 'Species') :: ['rhesus monkey']

entities_list: @entity774 :: ('MESH:D000312', 'Disease') :: ['hypothalamo-pituitary-adrenal (HPA) axis']

answer: @entity53 :: (MESH:D004958,Chemical) :: ['estradiol']


abstract: PURPOSE. This study investigated @entity1 telomerase RNA gene ( @entity7066 ) gain and polysomy of chromosome 3 in cervicovaginal liquid-based pap preparations in Guilin, China, and assessed the relationship between FISH findings and clinical diagnoses. METHODS. Slides prepared from 63 liquid-based preparations with cytologic diagnoses of negative for @entity2784 or @entity5 (NILM n = 9), atypical squamous cells of undetermined significance (ASCUS, n = 18), @entity2784 ( @entity2784 , n = 14), @entity2784 ( @entity2784 , n = 9), and @entity957 ( @entity957 , n = 13) were analyzed for @entity7066 gain and polysomy of chromosome 3 using a commercially available two-color FISH probe. The results of the cytologic analysis and those of concurrent or subsequent biopsies, when available, were compared with the FISH findings. The Mann-Whitney test was used to assess associations between FISH findings and diagnoses. RESULTS. @entity7066 gain and polysomy of chromosome 3 were significantly associated with the cytologic diagnosis (p? 0.001). @entity1 with @entity2784 or @entity957 cytology diagnoses had a significantly higher percentage of cells with @entity7066 gain and polysomy of chromosome 3 than did @entity1 with NILM, ASCUS or @entity2784 cytologic diagnoses. Those abnormal cases with CIN1 histological diagnosis had a significantly lower percentage of cells with @entity7066 gain and polysomy of chromosome 3 than did @entity1 with a CIN2, CIN3 and @entity957 histological diagnosis. CONCLUSIONS. @entity7066 gain and polysomy of chromosome 3 may be important associated genetic events in @entity2622 . FISH is a potential tool for the diagnoses of uterine cervix disease.

title: XXXX telomerase RNA gene ( @entity7066 ) gain and polysomy of chromosome 3 in cervicovaginal liquid-based pap preparations: a fluorescence in situ hybridization study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'human', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['cervical squamous cell carcinoma', 'SCCA']

entities_list: @entity2622 :: ('MESH:D002583', 'Disease') :: ['cervical intraepithelial neoplasia and carcinoma']

entities_list: @entity2784 :: ('MESH:D065310', 'Disease') :: ['squamous intraepithelial lesion', 'low-grade squamous intraepithelial lesion', 'LSIL', 'HSIL', 'high-grade squamous intraepithelial lesion']

answer: @entity1 :: (9606,Species) :: ['Human']


abstract: BACKGROUND AND OBJECTIVE: Local anaesthetics via a nerve block can attenuate @entity32 . However, their effects have never been compared with the anti-inflammatory effects of systemic NSAIDs. The aim of this study was to compare the effects of @entity1341 via @entity616 with a systemic NSAID on @entity4 and @entity1931 and on indices of systemic @entity32 as measured by cytokines and @entity1421 production in a model of @entity32 in @entity35 . METHODS: @entity35 (n=56) randomly received three injections: a left subcutaneous hind paw injection (carrageenan or physiological saline); a @entity714 ( @entity1341 or physiological saline); and a systemic injection ( @entity7988 or physiological saline). Six hours later, local @entity4 , thermal and mechanical @entity1931 as well as cerebrospinal fluid @entity1421 concentration and @entity5 necrosis factor-alpha and @entity3426 -stimulated production in whole blood cultures were measured. RESULTS: A @entity616 with @entity1341 as well as a systemic injection of NSAID significantly decreased the @entity4 and the thermal and mechanical @entity1931 induced by carrageenan. @entity4 was decreased by approximately 12%, and thermal and mechanical thresholds were increased by three-fold to fourfold and 1.5-2-fold, respectively. They both inhibited the increased production of @entity1421 in cerebrospinal fluid and @entity5 necrosis factor-alpha and @entity3426 in stimulated whole blood induced by carrageenan. There was no further benefit of the combination of a @entity616 and systemic NSAID. CONCLUSION: In the current study, a @entity1341 block alone achieved the same anti-inflammatory effect as systemic NSAID or as when the same block is combined with a NSAID.

title: Comparison of a XXXX peripheral nerve block and systemic @entity7988 on @entity32 and @entity1931 in @entity35 .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'peripheral inflammation']

entities_list: @entity7988 :: ('MESH:D007660', 'Chemical') :: ['ketoprofen']

entities_list: @entity1931 :: ('MESH:D006930', 'Disease') :: ['hyperalgesia']

entities_list: @entity714 :: ('MESH:D002037', 'Disease') :: ['left sciatic block']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['Oedema', 'oedema']

entities_list: @entity1421 :: ('MESH:D015232', 'Chemical') :: ['prostaglandin E2']

entities_list: @entity1341 :: ('MESH:D002045', 'Chemical') :: ['bupivacaine']

entities_list: @entity616 :: ('MESH:D006327', 'Disease') :: ['sciatic block']

answer: @entity1341 :: (MESH:D002045,Chemical) :: ['bupivacaine']


abstract: CONTEXT: Postmenopausal @entity3556 is a common clinical problem. Endovaginal ultrasound (EVUS) is a noninvasive diagnostic test that may help determine which @entity1 should undergo endometrial biopsy. OBJECTIVE: To determine the accuracy of EVUS in detecting @entity1478 in postmenopausal @entity1 with @entity3556 according to hormone replacement use. DATA SOURCES: Literature search of English-language and non-English-language articles published from 1966 through November 1996 using MEDLINE and by a manual search of bibliographies of published articles. STUDY SELECTION: Studies were included if they prospectively collected EVUS measurements of endometrial thickness prior to obtaining endometrial tissue for histologic evaluation in postmenopausal @entity1 with @entity3556 . Of 85 studies that included data on EVUS and endometrial histology, 35 were included in the meta-analysis and included 5892 @entity1 . DATA EXTRACTION: Articles were reviewed and independently selected and abstracted by 2 reviewers. Disagreement was resolved by consensus. DATA SYNTHESIS: The overall summary mean weighted estimates of sensitivity and specificity were calculated for thresholds of endometrial thickness from 3 to 10 mm. Using a 5-mm threshold to define abnormal endometrial thickening, 96% (95% confidence interval [CI], 94%-98%) of @entity1 with @entity5 had an abnormal EVUS result, whereas 92% (95% CI, 90%-93%) of @entity1 with @entity1478 ( @entity5 , @entity1127 , or @entity1373 ) had an abnormal result. This did not vary by hormone replacement use. However, the number of @entity1 with normal histology who had an abnormal EVUS result did vary by hormone replacement use. In @entity1 who were not using hormone replacement therapy, 593 (8%) with normal histological findings had an abnormal EVUS result (specificity, 92%; 95% CI, 90%-94%), whereas 1544 (23%) using hormone replacement therapy had an abnormal EVUS result (specificity, 77%; 95% CI, 75%-79%). For a postmenopausal @entity1 with @entity3556 with a 10% pretest probability of @entity1204 , her probability of @entity5 is 1% following a normal EVUS result. CONCLUSION: Endovaginal ultrasound has a high sensitivity for detecting @entity1204 and other @entity1478 and can reliably identify postmenopausal @entity1 with @entity3556 who are highly unlikely to have significant @entity1478 so that endometrial sampling may be unnecessary.

title: Endovaginal ultrasound to exclude XXXX and other @entity1478 .

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer']

entities_list: @entity3556 :: ('MESH:D014592', 'Disease') :: ['vaginal bleeding']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['atypical hyperplasia']

entities_list: @entity1478 :: ('MESH:D014591', 'Disease') :: ['endometrial disease']

answer: @entity1204 :: (MESH:D016889,Disease) :: ['endometrial cancer']


abstract: OBJECTIVE: To evaluate the efficacy and safety of botulinum toxin type A (BoNT-A) injected intra-articularly in 60 subjects with moderate @entity2531 secondary to knee @entity571 . The study investigators hypothesized that intra-articular BoNT-A would result in statistically significant improvements in @entity158 and function at 8 weeks. DESIGN: Double-blind, randomized, single tertiary care academic medical center trial with 6-month follow-up. @entity1 : Sixty @entity1 aged 40 years or older with painful @entity571 of the knee who had failed physical therapy, medications, and/or injection therapy presenting to the musculoskeletal or orthopedic outpatient clinics at a large tertiary care medical institution. All 60 @entity1 completed 8-week follow-up, but only 32 @entity1 completed the 26-week follow-up. METHODS: Subjects were randomized to receive a single injection of corticosteroid, low-dose BoNT-A (100 units), or high-dose BoNT-A (200 units). Outcome measures were compared at baseline, 4, 8, 12, and 26 weeks after injection. MAIN OUTCOME MEASUREMENTS: The primary outcome measure was @entity158 visual analog scale (VAS) at 8 weeks. Secondary outcome measures included Western Ontario @entity625 Index, Short Form-36 scores, @entity1 global assessment, 40-meter timed walk, and adverse effects. RESULTS: The primary end point was @entity158 VAS score at 8 weeks, which decreased within each group but only reached statistical significance in the low-dose BoNT-A group. In the intra-articular @entity228 group, VAS decreased from 6.4 +/- 1.8 to 5.4 +/- 2.3 (P = .15); for low-dose BoNT-A, from 6.6. +/- 1.9 to 4.5 +/- 2.2 (P = .01); and for high-dose BoNT-A, from 6.6 +/- 1.4 to 5.9 +/- 2.4 (P = .15). All groups showed statistically significant improvements in Western Ontario @entity625 Index scores ( @entity158 , stiffness, function) at 8 weeks. No serious adverse events were noted in any group. CONCLUSIONS: This pilot study supports a possible role for BoNT-A as a treatment option for symptomatic knee @entity571 ; however, larger double-blind randomized studies are needed to determine whether @entity7124 is more effective than placebo in this @entity1 population.

title: Efficacy of intra-articular botulinum toxin type A in XXXX : a pilot study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity571 :: ('MESH:D010003', 'Disease') :: ['osteoarthritis']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['McMaster Arthritis']

entities_list: @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid']

entities_list: @entity2531 :: ('MESH:D013001', 'Disease') :: ['pain and functional impairment']

answer: @entity158 :: (MESH:D010146,Disease) :: ['painful knee osteoarthritis']


abstract: INTRODUCTION AND OBJECTIVES: Symptomatic @entity339 has an unfavorable prognosis unless treated by surgery. However, the European registry of @entity340 reports that 49% of @entity1 with this condition do not undergo surgery. Percutaneous treatment of @entity339 with MitraClip   has been proved a safe, efficient adjunct to medical treatment in @entity1 with this profile. The objective of the present study is to describe initial experience of MitraClip   therapy in Spain. METHODS: Retrospective observational study including all @entity1 treated between November 2011 and July 2013 at the 4 Spanish hospitals recording the highest numbers of implantations. RESULTS: A total of 62 @entity1 (77.4% @entity1 ) were treated, mainly for restrictive functional @entity339 (85.4%) of grade III (37%) or grade IV (63%), mean (standard deviation) ejection fraction 36% (14%), and New York Heart Association functional class III (37%) or IV (63%). Device implantation was successful in 98% of the @entity1 . At 1 year, 81.2% had @entity339  <= 2 and 90.9% were in New York Heart Association functional class  <= II. One periprocedural @entity204 occurred ( @entity295 at 20 days post-implantation) and another 3 @entity1 died during follow-up (mean, 9.1 months). Two @entity1 needed a second implantation due to partial dehiscence of the first device and 2 others underwent heart transplantation. CONCLUSIONS: In Spain, MitraClip   therapy has principally been aimed at @entity1 with functional @entity339 , significant systolic @entity67 , and high surgical risk. It is considered a safe alternative treatment, which can reduce @entity339 and improve functional capacity.

title: Initial experience of percutaneous treatment of XXXX with MitraClip   therapy in Spain.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity339 :: ('MESH:D008944', 'Disease') :: ['mitral regurgitation']

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['ventricular dysfunction']

entities_list: @entity340 :: ('MESH:D006349', 'Disease') :: ['valvular heart disease']

answer: @entity339 :: (MESH:D008944,Disease) :: ['mitral regurgitation']


abstract: BACKGROUND: @entity14752 , also called steroid-responsive @entity75 associated with @entity1669 (SREAT), is a rare syndrome with an unknown pathogenesis. Clinical onset is insidious or acute with variable @entity16 . Spinal protein is elevated in most cases, but findings are non-specific in routine blood tests and on cerebral CT and EEG. The most important diagnostic clue is elevated levels of thyroid antibodies, especially anti-thyroid peroxidase antibody (anti- @entity5787 ). Administration of @entity288 is the treatment of choice and usually results in complete recovery. CASE REPORT: A 66-year-old @entity1 had experienced @entity16 over a few weeks. On admission she demonstrated moderate @entity2026 , @entity400 and @entity2045 , but no other focal neurological signs. A cerebral CT scan and routine blood tests did not provide diagnostic clues. The cerebrospinal fluid protein level was markedly elevated, and treatment with antibiotic and antiviral agents against possible @entity198 was started. However, the clinical condition did not improve. Further testing showed elevated levels of anti thyroxine peroxidase (aTPO) antibodies. Based on this finding, and after exclusion of other causes, the @entity1 was diagnosed with @entity14752 . On treatment with systemic @entity230 , the clinical condition improved over a few days. CONCLUSION: @entity14752 is a rare syndrome. Still, it is important to diagnose @entity1 correctly. Treatment with @entity230 induces marked clinical improvement and usually confers a good prognosis.

title: [A 66-year-old @entity1 with confusion, XXXX , and @entity2045 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patients', 'patient']

entities_list: @entity198 :: ('MESH:D004660', 'Disease') :: ['encephalitis']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy']

entities_list: @entity1669 :: ('MESH:D013967', 'Disease') :: ['autoimmune thyroiditis']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['episodic neurological symptoms', 'neurological symptoms']

entities_list: @entity2045 :: ('MESH:D009207', 'Disease') :: ['myoclonus']

entities_list: @entity14752 :: ('MESH:C535841', 'Disease') :: ["Hashimoto's encephalitis", "Hashimoto's encephalopathy"]

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity2026 :: (MESH:D001037,Disease) :: ['aphasia']


abstract: BACKGROUND: @entity358 are dreaded complications in acute @entity1566 . The prevention of @entity55 is essential for reducing mortality and the period of hospitalization. @entity1282 occur frequently in @entity1 with cervical @entity1566 and are accompanied by @entity1173 with a high risk of @entity55 . @entity1 AND METHODS: In this study the identification and analysis of @entity1 with newly acquired cervical @entity1566 were carried out with respect to @entity1576 , treatment and prevention. RESULTS: A total of 27  @entity1 with a cervical @entity1566 ( @entity1688 ) were identified. Of these 20  @entity1 (74%) were identified with a @entity1282 and a high risk of @entity1173 . Of these @entity1 11 ( @entity970 group) received a percutaneous feeding tube ( @entity970 tube), 9  @entity1 (non- @entity970 group) with diagnosed @entity1282 were treated without @entity970 tube. A total of 6  @entity1 in the non- @entity970 group (67%) acquired @entity55 compared to 3 @entity1 (27%) in the @entity970 group. CONCLUSION: A @entity1282 is a major risk factor for a @entity358 after a cervical @entity1566 . An early placement of a @entity970 tube has a preventive effect with respect to @entity1174 in @entity1 with @entity1282 .

title: [ XXXX after @entity1566 . Placement of @entity970 tubes as effective prevention].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity1688 :: ('MESH:D011782', 'Disease') :: ['tetraplegia']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity1174 :: ('MESH:D011015', 'Disease') :: ['aspiration pneumonia']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary infection', 'Pulmonary infections']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory complications']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['swallowing disorder', 'Swallowing disorders', 'dysphagia']

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injuries', 'cord injuries', 'cord injury']

entities_list: @entity1173 :: ('MESH:D053120', 'Disease') :: ['aspiration']

answer: @entity1174 :: (MESH:D011015,Disease) :: ['Aspiration pneumonia']


abstract: Serial ECGs of 16 @entity1 with repetitive attacks of spontaneous angina in the CCU were studied from admission to the hospital to the follow-up phase at the cardiac clinic. Transient repolarization ECG changes occurring during unprovoked angina included ST-segment elevation and ST-segment @entity308 , alterations of T-wave amplitude and polarity, and pseudonormalization of previously inverted T-waves. In addition, QRS complexes were altered transiently during @entity662 . Such changes comprised augmentation or reduction of amplitude of R and S waves, widening of QRS complexes and a merging of R waves with the elevated ST-segments. Occasionally the ECG during attacks of angina did not show any change. During asymptomatic periods, between attacks of spontaneous angina, the ECG either returned to baseline, or displayed minor ST-segment shifts, and/or T-wave alterations of varying durations. However, such changes became either persistent or were replaced in the late course of hospitalization by ECG alterations diagnostic of transmural or nontransmural @entity583 . Twelve @entity1 suffered an @entity583 . Four @entity1 died within one month of admission. During follow-up of the 12 surviving @entity1 in the cardiac clinic, amelioration of T-wave changes was noted in the ECGs of @entity1 who remained asymptomatic, but new @entity63 alterations were seen in the ECG of @entity1 who had recurrent angina, or were readmitted to the hospital for evaluation. Increase in the amplitude of R-waves, disappearance of Q-waves, or reduction of Q-wave depth were noted at follow-up, in comparison with the discharge ECG, in some @entity1 who had suffered primarily an anterior @entity583 .

title: Spontaneous angina in the coronary care unit. 2. Electrocardiographic changes during and after XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'acute myocardial infarction']

answer: @entity662 :: (MESH:D002637,Disease) :: ['chest pain']


abstract: Gender may produce different characteristics in the manifestation of @entity1252 ( @entity1252 ). The present study investigated the influence of gender on clinical, laboratory, autoantibodies and histopathological classes of @entity1988 ( @entity1988 ). As much as 81 @entity1 diagnosed with @entity1252 (ACR criteria) and active @entity1310 , who underwent renal biopsy between 1999 and 2004, and who had frozen serum samples and clinical data available from the time of biopsy, were selected for this study. The presence of anti-P and antichromatin antibodies was measured using ELISA, and anti-dsDNA was measured using indirect immunofluorescence. All of the renal biopsies were reviewed in a blinded manner by the same expert renal pathologist. The charts were extensively reviewed for demographic and renal features obtained at the time of the biopsy. Of the 81 @entity1 (13.6%), 11 were male @entity1252 @entity1 . Both male and female lupus @entity1 were of similar age and race, and had similar durations of @entity8 . The female @entity1 had more cutaneous (95.7 vs. 45.5%, P = 0.0001) and haematological (52.9 vs. 18.2%, P = 0.04) involvements than the male @entity1252 @entity1 . In addition, the articular data, central nervous system analyses, @entity11534 findings and SLEDAI scores were similar in both experimental groups. Positivity for anti-dsDNA, anti-ribosomal P and antichromatin did not differ between the two groups, and both groups showed similarly low C3 or C4 serum levels. Our analysis indicated that no histopathological class of @entity1988 was predominant in both males and females. Interestingly, the serum @entity1011 levels were higher in the male @entity1252 @entity1 compared to the female @entity1252 group (3.16 +/- 2.49 vs. 1.99 +/- 1.54 mg/dL, P = 0.03), with an increased frequency of high @entity1011 (81.8 vs. 47.1%, P = 0.04) as well as renal activity index (7.6 +/- 3.5 vs. 4.8 +/- 3.5, P = 0.02). In addition, whilst the mean levels of @entity644 , cylindruria and serum albumin were markedly altered, they were comparable between both lupus @entity1 and @entity1 . Moreover, the frequencies of dialysis, @entity8 were similar between the two groups. These data suggest that male @entity1 had a more severe @entity1988 compared to @entity1 diagnosed with this @entity8 .

title: Male gender results in more severe XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['men', 'women', 'patients']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity1310 :: ('MESH:D009393', 'Disease') :: ['nephritis']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal abnormality', 'lupus and renal disease', 'renal transplantation and death']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus']

entities_list: @entity1988 :: ('MESH:D008181', 'Disease') :: ['lupus nephritis', 'LN']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

answer: @entity1988 :: (MESH:D008181,Disease) :: ['lupus nephritis']


abstract: The objectives of this study were to evaluate the effect of somatic cell count ( @entity16517 ) on functional longevity and to estimate the heritability of functional longevity using survival analysis in Valle del Belice dairy @entity742 . A total of 4,880 lactations of 2,190 ewes from 11 flocks were used. In this study, @entity16517 was considered as an indication of subclinical @entity1271 . In case of clinical cases, identified by the technicians at milking time, test-day weights and milk samples of those ewes were not considered. Somatic cells were analyzed as counts, without any transformation, and were grouped in 3 classes based on the observed @entity16517 maximum (mxSCC). The mxSCC classes, expressed as 10(3) cells/mL, were classified as 1 if mxSCC <or= 500, 2 if 500 < mxSCC < 1,000, and 3 if mxSCC >or= 1,000. An increase in @entity16517 was associated with an increased hazard of being culled. Ewes in the highest class of @entity16517 on a test-day had a 20% higher hazard of being culled than those in the lowest class. Therefore, @entity16517 played a role in culling decisions of Valle del Belice dairy @entity742 farmers. The heritability estimate for functional longevity was 7% on the logarithmic scale and 11% on the real scale, indicating that selection for this trait is possible in @entity742 . The flock-year-season effect explained 19% of the variation on the logarithmic scale and 27% of the variation on the real scale.

title: Effect of somatic cell count level on functional longevity in Valle del Belice dairy XXXX assessed using survival analysis.

answer: @entity742 :: (9940,Species) :: ['sheep']


abstract: AIMS: [Formula: see text] multislice multiecho cardiac magnetic resonance (CMR) allows quantification of the segmental distribution of myocardial @entity68 overload (MIO). We evaluated whether a preferential pattern MIO was preserved between two CMR scans in regularly chelated @entity3173 ( @entity3173 ) @entity1 . METHODS AND RESULTS: We evaluated prospectively 259 @entity3173 @entity1 enrolled in the MIO in Thalassaemia (MIOT) network with a CMR follow-up (FU) study at 18    3 months and significant MIO at baseline. The [Formula: see text] in the 16 segments and the global value were calculated. Four main circumferential regions (anterior, septal, inferior and lateral) were defined. We identified two groups: severe (n = 80, global [Formula: see text] <10 ms) and mild-moderate MIO (n = 179, global [Formula: see text] = 10-26 ms). Based on the CMR reports, 56.4% of @entity1 changed the chelation regimen. For each group, there was a significant improvement in the global heart as well as in regional [Formula: see text] values (P < 0.0001). At the baseline, the mean [Formula: see text] value over the anterior region was significantly lower than the values over the other regions, and the mean [Formula: see text] over the inferior region was significantly lower than the values over the septal and the lateral regions. The same pattern was present at the FU, with a little difference for @entity1 with mild-moderate MIO. CONCLUSION: A preferential pattern of @entity68 store in anterior and inferior regions was present at both CMRs, with an increment of [Formula: see text] values at FU due to a baseline CMR-guided chelation therapy. The anterior region seems the region in which the @entity68 accumulates first and is removed later.

title: Improvement of heart @entity68 with preserved patterns of XXXX store by CMR-guided chelation therapy.

entities_list: @entity3173 :: ('MESH:D004830', 'Disease') :: ['thalassaemia major', 'TM']

answer: @entity68 :: (MESH:D007501,Chemical) :: ['iron']


abstract: We examined whether increased sympathetic nerve activity (SNA) accounts for enhanced @entity9598 responses to ganglionic blockade in the @entity8767 ( @entity8767 ) model of @entity740 ( @entity740 ) or whether it reflects increased vascular responses to vasodilation (vascular amplifier). Under @entity4774 anesthesia, @entity9598 responses to ganglionic blockade ( @entity4033 , 0.5-40 mg/kg i.v.), and direct vasodilation ( @entity1854 [SNP], 2.5-40  g/kg i.v. and @entity859 , 3-300  g/kg i.v.) were compared in the @entity8767 with normotensive Lewis and spontaneously @entity101 @entity35 (SHR) (total n = 37). @entity4033 (8 mg/kg) produced a greater @entity9598 response in the @entity8767 (-51    3 mmHg) compared with Lewis (-31    3 mmHg, P < 0.05) but not SHR (-46    3 mmHg). In @entity8767 , the ratio of the @entity4033 /vasodilator MAP responses was greater when compared with Lewis ( @entity4033 /SNP 1.34    0.1 vs. 0.9    0.09 and @entity4033 / @entity859 : 2.28    0.3 vs. 1.16    0.1, both P < 0.05) but not SHR. Results for systolic blood pressure (SBP) were comparable. The slope of the relationship between the fall in SBP induced by @entity4033 and normalized low frequency (LFnu) power was also greater in the @entity8767 (17.93    3.26 mmHg/LFnu) compared with Lewis (2.78    0.59 mmHg/LFnu, P = 0.001) and SHR (3.36   0.72 mmHg/LFnu, P = 0.003). These results indicate that in the @entity8767 , sympathetic activity predominates over any vascular amplifier effect, supporting increased sympathetic vasomotor tone as a major contributor to @entity101 in this model of @entity740 .

title: Sympathetic overactivity prevails over the vascular amplifier phenomena in a XXXX @entity35 model of @entity101 .

entities_list: @entity4033 :: ('MESH:D018738', 'Chemical') :: ['Hexamethonium', 'hexamethonium']

entities_list: @entity859 :: ('MESH:D000241', 'Chemical') :: ['adenosine']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive']

entities_list: @entity9598 :: ('MESH:C535349', 'Disease') :: ['depressor']

entities_list: @entity4774 :: ('MESH:D014520', 'Chemical') :: ['urethane']

entities_list: @entity1854 :: ('MESH:D009599', 'Chemical') :: ['sodium nitroprusside']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'chronic kidney disease']

entities_list: @entity8767 :: ('MESH:D007690', 'Disease') :: ['LPK', 'Lewis polycystic kidney']

answer: @entity740 :: (MESH:D051436,Disease) :: ['chronic kidney disease']


abstract: OBJECTIVE: @entity11669 , an a-glucosidase inhibitor, has been shown to have antineoplastic effects on @entity14 in biomarker studies. We assessed the association between @entity11669 use in @entity1 with @entity6 and incident @entity14 . RESEARCH DESIGN AND METHODS: We conducted a nationwide, population-based study using a large cohort with @entity6 in the Taiwan National Health Insurance Research Database. @entity1 with newly diagnosed @entity6 (n = 1,343,484) were enrolled between 1998 and 2010. One control subject not using @entity11669 was randomly selected for each subject using @entity11669 after matching for age, sex, @entity6 onset, and comorbidities. Cox proportional hazards regression with a competing risks analysis was used to calculate the hazard ratios (HRs) and 95% CIs for the association between @entity11669 use and incident @entity14 for each eligible case-control pair (n = 199,296). RESULTS: There were 1,332 incident cases of @entity14 in the cohort with @entity6 during the follow-up period of 1,487,136 @entity1 -years. The overall incidence rate was 89.6 cases per 100,000 @entity1 -years. @entity1 treated with @entity11669 had a 27% reduction in the risk of @entity14 compared with control subjects. The adjusted HRs were 0.73 (95% CI 0.63-0.83), 0.69 (0.59-0.82), and 0.46 (0.37-0.58) for @entity1 using >0 to <90, 90 to 364, and >= 365 cumulative defined daily doses of @entity11669 , respectively, compared with subjects who did not use @entity11669 (P for trend < 0.001). CONCLUSIONS: @entity11669 use reduced the risk of incident @entity14 in @entity1 with @entity6 in a dose-dependent manner.

title: Use of an a-Glucosidase Inhibitor and the Risk of @entity14 in @entity1 With XXXX : A Nationwide, Population-Based Cohort Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'person']

entities_list: @entity11669 :: ('MESH:D020909', 'Chemical') :: ['acarbose', 'Acarbose']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

answer: @entity6 :: (MESH:D003920,Disease) :: ['Diabetes']


abstract: The data bearing on these three cases are quite sufficient to rule out Bacillus abortus as the agent. Not only the cultures and @entity840 tests of fetal tissues and contents of the digestive tract, but also the agglutination and @entity840 tests of the milk, were negative. The same is true of the agglutination tests of the blood serum. Only in one case was the placenta obtained in part. The stained films and the sections from various regions showed no abortion bacilli. @entity840 tests of placental tissue were negative for Bacillus abortus. On the other hand) minute organisms resembling vibrios were detected in the cytoplasm of endothelial cells within capillaries in the @entity4 subchorionic tissue. Subsequently the agglutination titer of the blood serum of one of these cases rose to a level indicating @entity281 with Bacillus abortus during the second pregnancy. The peculiar distribution of abortions due to @entity5874 among older @entity291 and heifers in this herd, resulting at first in cases among older @entity291 and latterly passing to young stock, may be explained by certain occurrences in the herd itself. It may be assumed that the @entity281 was originally brought in by purchased @entity291 . The young stock is kept segregated from these in a special barn, and when 6 months old it is pastured on outlying farms until returned in an advanced stage of pregnancy. The heifers during the first pregnancy were thus kept away from vibrio carriers until after the first @entity291 was born. In June and July, 1919, 55 older @entity291 , purchased and native, were placed on the young stock pasture. The three cases of abortion in heifers due to @entity5874 occurred October 24, November 9, and December 2, 1919. The age and condition of the fetuses accord very well with the assumption that @entity5874 was introduced among the young stock in June or July of the same year. The information gathered thus far concerning @entity5852 in this herd enables us to formulate a tentative hypothesis subject to modification with increasing knowledge of this type of infectious abortion. The infectious agent was probably introduced by purchased @entity291 in 1917 or earlier. It gained a certain headway up to 1919, then the number of cases declined so that between May, 1919, and May, 1920, only the above three cases in heifers, and one case of @entity325 with Bacillus abortus in an older @entity291 , were detected. During the same period cases due to Bacillus abortus continued undiminished. The greater resistance of Bacillus abortus manifested in cultures as compared with @entity5874 is thus reflected in its behavior in nature. The temporary dying out of the @entity281 indicates that natural immunization of a herd to @entity5874 proceeds quite rapidly. Another outbreak may be expected when the immunity of the herd has declined in the absence of the infecting agent and the latter is reintroduced from without, or it may reappear at any time when a vibrio of higher virulence is brought in.

title: FURTHER STUDIES ON THE ETIOLOGICAL ROLE OF XXXX .

entities_list: @entity5852 :: ('MESH:D000031', 'Disease') :: ['vibrionic abortion']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['edematous']

entities_list: @entity840 :: ('10141', 'Species') :: ['Guinea pig', 'guinea pig']

entities_list: @entity5874 :: ('196', 'Species') :: ['Vibrio fetus']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity325 :: ('MESH:D060085', 'Disease') :: ['mixed infection']

answer: @entity5874 :: (196,Species) :: ['VIBRIO FETUS']


abstract: @entity927 ( @entity928 ), an inhibitor of fibrinolysis, reduces @entity190 after total knee arthroplasty. However, its effect on minimally invasive @entity572 ( @entity572 ) is not clear. We performed a prospective, randomised double-blind study to evaluate the effect of two intravenous injections of @entity928 on @entity190 in @entity1 undergoing minimally invasive @entity572 . In total, 60 @entity1 (35 @entity1 and 25 @entity1 with a mean age of 58.1 years; 17 to 84) who underwent unilateral minimally invasive uncemented @entity572 were randomly divided into the study group (30 @entity1 , 20 @entity1 and ten @entity1 with a mean age of 56.5 years; 17 to 79) that received two intravenous injections 1 g of @entity928 pre- and post-operatively ( @entity928 group), and a placebo group (30 @entity1 , 15 @entity1 and 15 @entity1 with a mean age of 59.5 years; 23 to 84). We compared the peri-operative @entity190 of the two groups. Actual @entity190 was calculated from the maximum reduction in the level of haemoglobin. All @entity1 were followed clinically for the presence of @entity1211 . The @entity928 group had a lower mean intra-operative @entity190 of 441 ml (150 to 800) versus 615 ml (50 to 1580) in the placebo (p = 0.044), lower mean post-operative @entity190 (285 ml (120 to 570) versus 392 ml (126 to 660) (p = 0.002), @entity190 (1070 ml (688 to 1478) versus 1337 ml (495 to 2238) (p = 0.004) and lower requirement for transfusion (p  =  0.021). No @entity1 in either group had symptoms of @entity1211 or wound complications. This prospective, randomised controlled study showed that a regimen of two intravenous injections of 1 g @entity928 is effective for blood conservation after minimally invasive @entity572 . Cite this article: Bone Joint J 2015;97-B:905-10.

title: A regime of two intravenous injections of @entity927 reduces XXXX in minimally invasive @entity572 : a prospective randomised double-blind study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['lower mean total blood loss', 'blood loss']

entities_list: @entity572 :: ('MESH:D006617', 'Disease') :: ['THA', 'total hip arthroplasty']

entities_list: @entity927 :: ('MESH:D014148', 'Chemical') :: ['Tranexamic acid']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thromboembolism']

answer: @entity190 :: (MESH:D006473,Disease) :: ['blood loss']


abstract: BACKGROUND: @entity3528 is a common feature in @entity1 with @entity740 . Its serious clinical consequences include @entity8 , @entity729 that increase morbidity and mortality.Reduced synthesis of active @entity560 contributes to @entity3528 . Therefore, this condition is managed with activated @entity560 . However, @entity2741 and @entity2265 limit the use of activated @entity560 .In Denmark @entity15199 is the primary choice of @entity560 analog.A new @entity560 analog, @entity21453 , may be less prone to induce @entity2741 and @entity2265 .However, a randomised controlled clinical study comparing @entity15199 and @entity21453 has never been performed.The primary objective of this study is to compare @entity15199 and @entity21453 . We evaluate the suppression of the @entity3528 and the tendency towards @entity2265 and @entity2741 . METHODS/DESIGN: This is an investigator-initiated cross-over study. Nine Danish haemodialysis units will recruit 117 @entity1 with end @entity177 on maintenance haemodialysis therapy. @entity1 are randomised into two treatment arms. After a wash out period of 6 weeks they receive increasing doses of @entity15199 or @entity21453 for a period of 16 weeks and after a further wash out period of 6 weeks they receive the contrary treatment ( @entity21453 or @entity15199 ) for 16 weeks. DISCUSSION: @entity2742 , @entity2741 and @entity2265 are associated with increased @entity65 in @entity1 with @entity740 .If there is any difference in the ability of these two @entity560 analogs to decrease the @entity3528 without causing @entity2741 and @entity2265 , there may also be a difference in the risk of @entity65 depending on which @entity560 analog that are used. This has potential major importance for this group of @entity1 . TRIAL REGISTRATION: ClinicalTrials.gov NCT00469599.

title: Treatment of @entity3528 in haemodialysis XXXX : a randomised clinical trial comparing @entity21453 and @entity15199 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal osteodystrophy']

entities_list: @entity2741 :: ('MESH:D006934', 'Disease') :: ['hypercalcemia']

entities_list: @entity3528 :: ('MESH:D006962', 'Disease') :: ['Secondary hyperparathyroidism', 'secondary hyperparathyroidism']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic kidney disease']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['stage renal failure']

entities_list: @entity2265 :: ('MESH:D054559', 'Disease') :: ['hyperphosphatemia']

entities_list: @entity21453 :: ('MESH:C084656', 'Chemical') :: ['paricalcitol']

entities_list: @entity729 :: ('MESH:D061205', 'Disease') :: ['calcific uremic arteriolopathy, and vascular calcifications']

entities_list: @entity15199 :: ('MESH:C008088', 'Chemical') :: ['alfacalcidol']

entities_list: @entity2742 :: ('MESH:D006961', 'Disease') :: ['Hyperparathyroidism']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular mortality']

entities_list: @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVES: To describe the comorbidity of @entity227 and disability among @entity1 hospitalized for @entity262 and to discuss rehabilitation. DESIGN: Retrospective study. SETTING: Hospital-based, academic tertiary medical center with referring neurology, ophthalmology, and rehabilitation units. @entity1 : Ninety-three hospitalized @entity1 referred to the @entity4064 rehabilitation clinic primarily by the physical medicine and rehabilitation and neurology units. INTERVENTIONS: Measurements of best-corrected visual acuity and other visual function testing. Referrals were made for prescriptive glasses, assistive devices, rehabilitation, resources, and ophthalmologic evaluation. MAIN OUTCOME MEASURES: Specialized services, presence of comorbidities, and visual function measurements. RESULTS: The mean admitting visual acuity revealed a moderate @entity227 . The primary diagnosis for admission (51%) was @entity64 . There was a mean of 3.5 other comorbidities. CONCLUSIONS: The majority of @entity1 admitted to the hospital for @entity262 also had @entity227 . In many @entity1 , this @entity227 (either from the @entity2194 ) interfered with their activities of daily living.

title: Rehabilitation of hospital inpatients with @entity227 and disabilities from XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual disability', 'visual impairments', 'visual impairment']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['cerebrovascular accidents']

entities_list: @entity2194 :: ('MESH:D005128', 'Disease') :: ['systemic and/or ocular disease']

entities_list: @entity262 :: ('MESH:D034721', 'Disease') :: ['systemic illness', 'systemic diseases']

entities_list: @entity4064 :: ('MESH:D015354', 'Disease') :: ['low vision']

answer: @entity262 :: (MESH:D034721,Disease) :: ['systemic illness']


abstract: Our phase I Hepatic Immunotherapy for @entity3 (HITM) trial tested the safety of @entity784 (CAR-T) hepatic artery infusions (HAI) for unresectable @entity10580 ( @entity10580 )+ liver @entity3 (LM). High neutrophil:lymphocyte ratios (NLR) predict poor outcome in @entity5 @entity1 and we hypothesized that NLR changes would correlate with early responses to @entity784 HAI. Six @entity1 completed the protocol. Three @entity1 received @entity784 HAI in dose escalation (1 * 10(8), 1 * 10(9) and 1 * 10(10) cells) and the remainder received three doses (1 * 10(10) cells) with interleukin (IL)2 support. Serum cytokines and NLR were measured at multiple time points. The mean NLR for all @entity1 was 13.9 (range 4.8-38.1). NLR increased in four @entity1 following treatment with a mean fold change of 1.9. Serum @entity650 levels and NLR fold changes demonstrated a trend towards a positive correlation (r=0.77, P=0.10). @entity1 with poor @entity10580 responses were significantly more likely to have higher NLR level increases (P=0.048). Increased NLR levels were associated with poor responses following @entity784 HAI. NLR variations and associated cytokine changes may be useful surrogates of response to @entity784 HAI.

title: Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery XXXX infusions for liver @entity3 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity784 :: ('MESH:D016399', 'Disease') :: ['CAR-T', 'chimeric antigen receptor-modified T-cell']

entities_list: @entity10580 :: ('1048', 'Gene') :: ['CEA', 'carcinoembryonic antigen']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases', 'Metastases']

answer: @entity784 :: (MESH:D016399,Disease) :: ['chimeric antigen receptor-modified T-cell']


abstract: The objective of this study was to perform intracytoplasmic sperm injection (ICSI) on in vitro matured @entity1641 oocytes and to improve in vitro embryonic development on Vero cells after activation of the microinjected oocytes with @entity460 ionophore. After maturation (23 or 40 h, 38.5 degrees C, 5% @entity515 ), the cumulus-oocyte complexes were denuded, centrifuged and all oocytes exhibiting the first polar body were microinjected. ICSI was performed using fresh semen from three fertile stallions. Microinjected oocytes were activated with @entity460 ionophore @entity3365 (10 min, 10 microM) and cultured individually for 7 days on Vero cells in microdrops. In seven trials, 353 cumulus-oocyte complexes were matured and 103 oocytes were microinjected. Eight oocytes were sham microinjected. After ICSI, 85 oocytes (82.5%) survived the sperm injection procedure. Among the 76 successfully microinjected oocytes, 52 (68%) were fertilized (two pronuclei, syngamy stage and cleaved ova). Sham microinjected oocytes were not activated. After in vitro culture, 35 ova (46%) were cleaved 2 days after ICSI and early embryonic development was obtained (three embryos of 23 cells, 50 cells and more than 80 cells) 5 to 7 days after ICSI.

title: Preliminary observations in in vitro development of XXXX embryo after ICSI.

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity1641 :: (9796,Species) :: ['equine']


abstract: OBJECTIVE: To identify early predictors of @entity8480 ( @entity8480 ) involvement in a cohort of @entity1 with @entity4932 ( @entity4932 ). METHODS: During a 7-year followup period, all consecutive @entity1 fulfilling the ILAR classification criteria for @entity4932 were enrolled. Data collected included demographic, clinical and laboratory variables at disease onset, at the onset of @entity615 , and at the last available followup visit. Pelvis radiographs and dynamic magnetic resonance imaging (MRI) scans for @entity8480 joints were obtained simultaneously in all @entity1 who developed @entity615 . RESULTS: Fifty-nine @entity1 with @entity4932 were studied; 40 male, 19 female; median age at disease onset 9 years 4 months (range 6 yrs 6 mo - 13 yrs 3 mo). At a median interval after disease onset of 1 year 3 months, 21 @entity1 reported symptoms of @entity615 . In all cases, radiographs of @entity8480 joints were negative, while dynamic MRI revealed acute @entity6592 in 17 cases. Multivariate analysis showed that the early predictors of @entity8480 were the number of active joints (p < 0.03) and the number of active entheses (p < 0.001) at onset. CONCLUSION: In our cohort, roughly 30% of @entity1 with @entity4932 /juvenile idiopathic @entity625 develop clinical and MRI evidence of @entity6592 , detectable with dynamic MRI as early as 1 year after disease onset. Additional data from larger case series are needed to assess the specificity and sensitivity of this technique in the early phase of the disease and to confirm the rate of @entity8480 involvement reported in this cohort.

title: Early predictors of @entity6592 in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity6592 :: ('MESH:D058566', 'Disease') :: ['sacroiliitis']

entities_list: @entity8480 :: ('MESH:C563037', 'Disease') :: ['SI', 'sacroiliac']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis']

entities_list: @entity4932 :: ('MESH:D001171', 'Disease') :: ['enthesitis-related arthritis', 'ERA']

entities_list: @entity615 :: ('MESH:D001416', 'Disease') :: ['inflammatory back pain']

answer: @entity4932 :: (MESH:D001171,Disease) :: ['enthesitis-related arthritis']


abstract: UNASSIGNED: A 69-year-old @entity1 presented with non-fluent @entity2026 , @entity8378 , @entity1269 and @entity410 . Her medical history was unremarkable, and she had not suffered from @entity625 . DWI and FLAIR image of brain MRI showed hyperintensities in the subarachnoid space along the left frontal and both parietal lobes, and these lesions were associated with @entity2287 enhancement. The levels of serum anti-cyclic citrullinated peptide antibody, anti-agalactosyl IgG antibody and matrix metalloproteinase-3 were elevated. The results of blood cultures were negative. Cerebrospinal fluid (CSF) analysis revealed monocytic pleocytosis and negative findings for @entity5 . The level of anti-agalactosyl IgG antibody in CSF was elevated. The antibody index (AI) of anti-agalactosyl IgG antibody (the ratio between the CSF/serum quotient for IgG antibodies, and the CSF/serum quotient for total IgG; normal value of AI < 1.3) showed considerably high value of 8.4, indicating the intrathecal-specific antibody synthesis. As a result, the pathogenesis of her disease was consistent with @entity693 despite lack of @entity625 . After intravenous administration of @entity1667 , her symptoms, the level of anti-agalactosyl IgG antibody in CSF, and the MRI findings were ameliorated. Anti-agalactosyl IgG antibody in the CSF was a helpful biomarker in diagnosis and assessment of the severity of @entity693 .

title: Aseptic meningitis in a XXXX with cerebrospinal fluid anti-agalactosyl IgG antibody-positive preclinical rheumatoid arthritis: a case report.

entities_list: @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['convulsion']

entities_list: @entity8378 :: ('MESH:D020240', 'Disease') :: ['ideomotor apraxia']

entities_list: @entity1269 :: ('MESH:D010291', 'Disease') :: ['right hemiparesis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['infection or malignancy']

entities_list: @entity693 :: ('MESH:D008581', 'Disease') :: ['rheumatoid meningitis']

entities_list: @entity2287 :: ('MESH:D005682', 'Chemical') :: ['gadolinium']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: OBJECTIVES: To compare the clinical diagnosis with the histopathological diagnosis; to highlight associated histological lesions and; to determine whether these provide additional useful information for management. DESIGN: Case series. SETTING: Pathology Department of the King Fahd Specialist Hospital in Buraidah, Saudi Arabia. SUBJECTS: 370 appendicectomy specimen reviewed within a 12 month period. MAIN OUTCOME MEASURES: Diagnostic accuracy of a clinical diagnosis of acute or @entity102 . RESULTS: @entity697 was found to be most common between ages 10 to 29 years (74.0%). The diagnostic accuracy was 81%. A higher rate of appendices without histological sign of @entity32 was found in females. Incidental appendicectomy was commonly associated with cholecystectomy. Unsuspected but treatable @entity2878 were detected in 3% of appendices. CONCLUSION: Routine examination of all appendicectomy specimens cannot be overemphasized, as unsuspected but treatable parasitic on @entity2878 may be detected.

title: XXXX in Buraidah, Saudi Arabia.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['Acute appendicitis']

entities_list: @entity2878 :: ('MESH:D020808', 'Disease') :: ['parasitic and protozoal infections', 'protozoal infections']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic appendicitis']

answer: @entity697 :: (MESH:D000208,Disease) :: ['Acute appendicitis']


abstract: OBJECTIVE: To evaluate the side effects of @entity1499 ( @entity1500 ) in @entity309 ( @entity309 ) @entity1 and to evaluate the possible predisposing variables. METHODS: A retrospective analysis conducted for all @entity1 diagnosed with @entity309 and treated with @entity1500 over 3-years (January 2006 to December 2008) at King Abdul-Aziz University Hospital, Jeddah, Kingdom of Saudi Arabia. Frequency of @entity1500 side effects and the predictive variables were recorded and analyzed statistically. RESULTS: Out of 116 @entity309 @entity1 , 71 @entity1 used @entity1500 . The most frequent side effect was @entity344 in 31%, followed by central nervous system symptoms in 18%, hepatotoxicity in 14%, @entity3136 and @entity1665 in 10% each, @entity11140 7%, @entity221 , @entity1910 and @entity3043 in 4%, and @entity1500 -induced @entity651 with increase in the size of rheumatoid nodule in 1% of @entity1 . By Logistic regression analysis, @entity8 was the most significant variable increasing the risk of the side effects (OR=7.14, p<0.05). Other associated variables were male-gender, non-Saudi nationality, smoking, @entity230 use, @entity4988 , and the presence of extra-articular manifestations. CONCLUSION: @entity1499 is the most commonly drug used in the treatment of @entity309 . @entity344 were the most common side effect while lung involvement was the least. The impact of each clinical variable on @entity1500 side effects requires paying more attention on the disease management as not all variables can be considered as risk factors.

title: Adverse effects of low dose XXXX in @entity309 @entity1 . A hospital-based study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment']

entities_list: @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis']

entities_list: @entity1910 :: ('MESH:D005076', 'Disease') :: ['malar rash']

entities_list: @entity4988 :: ('MESH:D034141', 'Disease') :: ['hypoalbuminemia']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal (GIT) disturbance', 'Gastrointestinal disturbances']

entities_list: @entity11140 :: ('MESH:C564004', 'Disease') :: ['macrocytosis']

entities_list: @entity651 :: ('MESH:D055370', 'Disease') :: ['lung injury']

entities_list: @entity3043 :: ('MESH:D010198', 'Disease') :: ['pancytopenia']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['Methotrexate', 'methotrexate']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

answer: @entity1499 :: (MESH:D008727,Chemical) :: ['methotrexate']


abstract: We measured the mRNA transcript expression patterns for members of the insulin-like growth factor (IGF) system during embryonic and postnatal development in epiphyseal cartilage from Langshan (LS) and Arbor Acres (AA) @entity1573 . @entity20018 expression was positively correlated with @entity2090 from embryonic day (E) 14 to postnatal d (P) 0 and with @entity20019 from E14 to P14 but negatively correlated with @entity2090 from P0 to @entity10491 and @entity20019 from P14 to @entity10491 . Expression of @entity20020 correlated positively with @entity2090 from E14 to P0 but negatively from P0 to P28. The results suggest that these genes are regulated in a coordinated fashion during development. A negative correlation was found between @entity20021 and @entity20019 during P0 to @entity10491 . A positive correlation was found between @entity20022 (E14 to E18, P14 to @entity10491 ) and IGF-IR and between @entity20022 (E14 to P0, P14 to @entity10491 ) and @entity2090 . The endocrine factors can be integrated with nutrition to regulate animal growth. In our study, AA @entity1573 were fed a nutrient-rich AA diet, and LS @entity1573 were fed either an AA diet or a less-rich diet. The LS and AA @entity1573 fed the same AA diet showed no differences in @entity2090 , @entity20023 , @entity20018 , @entity20020 , @entity20021 , and @entity20022 but did still show differences in @entity20019 . Our data indicate that these select genes may show linked expression during certain periods of development and that differences in gene expression respond differently to nutrient intake in LS and AA @entity1573 .

title: Role of the insulin-like growth factor system in epiphyseal cartilage on the development of Langshan and Arbor Acres @entity1573 , XXXX .

entities_list: @entity20018 :: ('396315(Tax:9031)', 'Gene') :: ['IGFBP-2', 'Insulin-like growth factor binding protein (IGFBP)-2']

answer: @entity1573 :: (9031,Species) :: ['Gallus domesticus']


abstract: The mechanism by which @entity116 toxin (TT) inhibits the release of neurotransmitters from neurons is unknown. Since secretion of lysosomal contents from @entity15835 ( @entity15835 ) appears to be similar to the release of synaptosomal contents from neural cells, we examined the effects of TT on MO secretion. Adherent @entity1 @entity15835 were cultured overnight with or without TT (1.25 micrograms/ml), washed, and resuspended in TT-free medium. In response to the @entity460 ionophore @entity3365 , TT-treated @entity15835 secreted significantly less @entity16977 (27.2% +/- 3.2%) than did control cells (48.6% +/- 6.8%; 44.1% inhibition, P less than .001). TT inhibition of @entity3365 -stimulated release of @entity16977 from @entity15835 was dose dependent, and higher concentrations of @entity3365 could not overcome the inhibitory effect of TT. MO secretions in response to a second secretagogue, @entity4514 , was also inhibited by TT. Heated TT (100 C for 1 hr), which has no in vivo @entity137 , also failed to inhibit MO secretion. The inhibition of secretion by TT required holotoxin. C- and B-fragments produced no appreciable effect on secretion in response to either secretagogue. These studies indicate that @entity1 @entity15835 may be a readily accessible, model system for the study of the biochemical basis of TT intoxication. However, observations in this system must be confirmed in neurons, the natural site of TT intoxication.

title: XXXX toxin inhibits secretion of lysosomal contents from @entity1 macrophages.

entities_list: @entity4514 :: ('MESH:D013755', 'Chemical') :: ['phorbol myristate acetate']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity15835 :: ('MESH:D055501', 'Disease') :: ['MOs', 'monocytes/macrophages']

answer: @entity116 :: (MESH:D013746,Disease) :: ['Tetanus']